Semprus BioSciences to Present at SIRs 36th Annual Scientific Meeting
Summary
The companys current focus is to develop a vascular access catheter with the first single surface modification that is designed to simultaneously reduce microbial adherence and thrombus accumulation over the life of the device.Its current focus is to develop a vascular access catheter with the first single surface modification that is designed to simultaneously reduce microbial adherence and thrombus accumulation over the life of the device.These data showcase the technologys three distinctive aspects: its dual-functionality, its ability to work in blood products, and its long-term durational advantages over existing surface and coating technologies.SIRs Annual Meeting is a recognized forum for peer-reviewed presentations of new research by interventional radiologists and allied scientists from around the world.The companys current focus is to develop a vascular access catheter with the first single surface modification that is designed to simultaneously reduce microbial adherence and thrombus accumulation over the life of the device.Loose will present at the Venous Access/Thrombolysis Scientific Session on Monday, March 28, at 8:30 a.m. in Room W181C, McCormick Place West Building.About Semprus BioSciencesSemprus BioSciences is a venture-backed biomedical company headquartered in Cambridge, Massachusetts.